The role of metformin in tuberculosis control among TB and diabetes mellitus comorbid individuals
Abstract
Tuberculosis (TB) is a major global health concern, and its control is particularly hindered in patients with comorbidities such as type 2 diabetes mellitus (TBDM). Metformin, a commonly prescribed antidiabetic medication, has gained attention because of its potential role in improving TB treatment outcomes in patients with TBDM. This review aims to assess the role of metformin in TB case management among TBDM comorbid individuals. By reviewing the available literature, we aimed to explore the potential benefits, complications, mechanisms, and considerations surrounding metformin use as an adjunctive therapy for TB treatment. The findings of this review will shed light on current understanding and highlight areas for further investigation.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.